Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$101M in Q4 2014 → $55.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2019. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| IT Ishares Tr | 22.5% | Unchanged | 125,000 | $12.4M |
| IT Ishares Tr Call | 15.3% | Unchanged | 85,000 | $8.46M |
| DS Direxion Shs ETF Tr | 5.6% | Added 1.4% | 99,855 | $3.09M |
| Mettler Toledo International | 4.1% | Unchanged | 3,235 | $2.28M |
| Bristol Myers Squibb Co | 3.0% | Unchanged | 33,000 | $1.67M |
| SG Seattle Genetics Inc | 2.8% | Added 0.7% | 18,020 | $1.54M |
| Illumina Inc | 2.6% | Added 0.5% | 4,721 | $1.44M |
| Vertex Pharmaceuticals Inc | 2.5% | Added 1.0% | 8,279 | $1.4M |
| Ionis Pharmaceuticals Inc | 2.2% | Unchanged | 20,124 | $1.21M |
| Alnylam Pharmaceuticals Inc | 2.0% | Added 2.5% | 13,684 | $1.1M |
| AP Alexion Pharmaceuticals Inc | 1.8% | Added 0.1% | 9,933 | $973K |
| QN Qiagen Nv | 1.7% | Unchanged | 28,858 | $951K |
| ST Spark Therapeutics Inc | 1.7% | Unchanged | 9,699 | $941K |
| Fortress Biotech Inc | 1.6% | Added 162% | 613,551 | $865K |
| PT Proqr Thrapeutics N V | 1.4% | Unchanged | 138,461 | $798K |
| Incyte Corp | 1.4% | Added 0.4% | 10,659 | $791K |
| Exact Sciences Corp | 1.4% | Unchanged | 8,534 | $771K |
| Regeneron Pharmaceuticals | 1.2% | Added 9.8% | 2,439 | $677K |
| Biomarin Pharmaceutical Inc | 1.2% | Added 3.2% | 9,700 | $654K |
| DP Deciphera Pharmaceuticals In | 1.1% | Unchanged | 18,631 | $632K |
| Ascendis Pharma A S | 1.1% | Unchanged | 6,190 | $596K |
| UN Uniqure Nv | 1.0% | Unchanged | 14,215 | $560K |
| C Celgene Corp | 1.0% | Unchanged | 5,625 | $559K |
| Crispr Therapeutics Ag | 1.0% | Unchanged | 13,214 | $542K |
| E Epizyme Inc | 0.9% | Unchanged | 50,378 | $520K |
| Amarin Corp PLC | 0.9% | Added 102% | 33,641 | $510K |
| Blueprint Medicines Corp | 0.9% | Unchanged | 6,780 | $498K |
| AT Audentes Therapeutics Inc | 0.9% | Unchanged | 17,339 | $487K |
| G1 Therapeutics Inc | 0.9% | Unchanged | 20,844 | $475K |
| GB Global Blood Therapeutics In | 0.8% | Unchanged | 9,479 | $460K |
| BP Biohaven Pharmactl Hldg Co L | 0.8% | Unchanged | 10,852 | $453K |
| AP Arena Pharmaceuticals Inc | 0.8% | Unchanged | 9,770 | $447K |
| Acadia Pharmaceuticals Inc | 0.8% | Added 0.2% | 12,005 | $432K |
| GP Gw Pharmaceuticals PLC | 0.8% | Unchanged | 3,674 | $423K |
| Z Zogenix Inc | 0.7% | Unchanged | 9,725 | $389K |
| Macrogenics Inc | 0.7% | Unchanged | 30,075 | $384K |
| Intellia Therapeutics Inc | 0.7% | Unchanged | 28,490 | $380K |
| Bio Techne Corp | 0.5% | Unchanged | 1,551 | $303K |
| IH Iqvia Hldgs Inc | 0.5% | Unchanged | 1,985 | $297K |
| Amgen Inc | 0.5% | Added 8.7% | 1,518 | $294K |
| Neurocrine Biosciences Inc | 0.5% | Added 3.8% | 3,127 | $282K |
| Checkpoint Therapeutics Inc | 0.5% | Unchanged | 112,760 | $281K |
| CR Charles Riv Labs Intl Inc | 0.5% | Unchanged | 2,112 | $280K |
| UT United Therapeutics Corp Del | 0.5% | New | 3,498 | $279K |
| GS Grifols S A | 0.5% | Unchanged | 13,196 | $264K |
| Biogen Inc | 0.5% | Unchanged | 1,123 | $261K |
| IP Intercept Pharmaceuticals In | 0.5% | Trimmed 33% | 3,926 | $261K |
| Gilead Sciences Inc | 0.5% | Unchanged | 4,082 | $259K |
| Ligand Pharmaceuticals Inc | 0.4% | Added 15% | 2,428 | $242K |
| Nektar Therapeutics | 0.4% | Added 3.4% | 12,927 | $235K |
| Exelixis Inc | 0.4% | Added 15% | 13,132 | $232K |
| Alkermes PLC | 0.4% | New | 11,632 | $227K |
| UP Ultragenyx Pharmaceutical In | 0.4% | Unchanged | 5,064 | $217K |
| F Fibrogen Inc | 0.4% | Added 18% | 5,742 | $212K |
| RP Recro Pharma Inc | 0.2% | Unchanged | 11,353 | $126K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2019 · filed November 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| I Immunomedics Inc | Exited | −62,575 | −$868K | — |
| Sarepta Therapeutics Inc | Exited | −5,353 | −$813K | — |
| Bluebird Bio Inc | Exited | −5,840 | −$743K | — |
| Insmed Inc | Exited | −26,936 | −$690K | — |
| Fortress Biotech Inc | Added | +379,521 | +$535K | 1.6% |
| Pacira Biosciences | Exited | −11,250 | −$489K | — |
| Amicus Therapeutics Inc | Exited | −36,731 | −$458K | — |
| Viking Therapeutics Inc | Exited | −48,485 | −$402K | — |
| Madrigal Pharmaceuticals Inc | Exited | −3,570 | −$374K | — |
| Anaptysbio Inc | Exited | −6,116 | −$345K | — |
Showing the 10 largest of 31 changes.
quarter ended June 30, 2019 · filed August 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Regenxbio Inc | Exited | −8,832 | −$506K | — |
| CS Cellectis S A | Exited | −22,309 | −$409K | — |
| Supernus Pharmaceuticals Inc | Exited | −11,648 | −$408K | — |
| Rubius Therapeutics Inc | Exited | −21,610 | −$391K | — |
| Wave Life Sciences Ltd | Exited | −9,716 | −$377K | — |
| Xencor Inc | Exited | −10,935 | −$340K | — |
| Sangamo Therapeutics Inc | Exited | −33,529 | −$320K | — |
| Sarepta Therapeutics Inc | Added | +2,101 | +$319K | 1.2% |
| Exact Sciences Corp | Added | +2,441 | +$288K | 1.5% |
| Alkermes PLC | Exited | −7,722 | −$282K | — |
Showing the 10 largest of 31 changes.
quarter ended March 31, 2019 · filed May 15, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| DS Direxion Shs ETF Tr | Added | +28,702 | +$1.72M | 8.0% |
| Bristol Myers Squibb Co | New | +33,000 | +$1.57M | 2.1% |
| I Immunomedics Inc | New | +62,575 | +$1.2M | 1.6% |
| ST Spark Therapeutics Inc | New | +9,699 | +$1.11M | 1.5% |
| LO Loxo Oncology Inc | Exited | −6,210 | −$870K | — |
| UN Uniqure Nv | New | +14,215 | +$848K | 1.1% |
| Insmed Inc | New | +26,936 | +$783K | 1.1% |
| Ascendis Pharma A S | New | +6,190 | +$729K | 1.0% |
| AT Audentes Therapeutics Inc | New | +17,339 | +$677K | 0.9% |
| E Epizyme Inc | New | +50,378 | +$624K | 0.8% |
Showing the 10 largest of 69 changes.
quarter ended December 31, 2018 · filed February 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IT Ishares Tr | New | +125,000 | +$12.1M | 26.5% |
| IT Ishares Tr | New | +85,000 | +$8.2M | 18.0% |
| T Tesaro Inc | Exited | −94,300 | −$3.68M | — |
| CO Clovis Oncology Inc | Exited | −82,430 | −$2.42M | — |
| DS Direxion Shs ETF Tr | New | +69,309 | +$2.28M | 5.0% |
| MP Mei Pharma Inc | Exited | −360,000 | −$1.55M | — |
| AP Achillion Pharmaceuticals In | Exited | −308,569 | −$1.14M | — |
| AP Adamas Pharmaceuticals Inc | Exited | −44,500 | −$891K | — |
| Alkermes PLC | Trimmed | −17,637 | −$519K | 0.5% |
| F Fibrogen Inc | Trimmed | −10,447 | −$484K | 0.7% |
Showing the 10 largest of 43 changes.
quarter ended September 30, 2018 · filed November 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Exited | −58,000 | −$5.52M | — |
| PT Proshares Tr | Exited | −93,805 | −$5.37M | — |
| T Tesaro Inc | Added | +82,800 | +$3.23M | 8.8% |
| IT Ishares Tr | Exited | −18,750 | −$2.06M | — |
| CO Clovis Oncology Inc | Added | +69,430 | +$2.04M | 5.8% |
| AP Achillion Pharmaceuticals In | New | +308,569 | +$1.14M | 2.7% |
| Biogen Inc | Trimmed | −2,500 | −$884K | 0.9% |
| Amgen Inc | Trimmed | −4,089 | −$848K | 0.9% |
| AP Adamas Pharmaceuticals Inc | Added | +29,500 | +$591K | 2.1% |
| Fortress Biotech Inc | New | +234,030 | +$374K | 0.9% |
Showing the 10 largest of 50 changes.
quarter ended June 30, 2018 · filed August 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PT Proshares Tr | Trimmed | −93,805 | −$5.37M | 11.6% |
| PT Proshares Tr | Exited | −60,000 | −$3.3M | — |
| SS SPDR Series Trust | Added | +34,200 | +$3.26M | 12.0% |
| MP Mei Pharma Inc | New | +400,000 | +$1.58M | 3.4% |
| Nektar Therapeutics | Trimmed | −14,899 | −$728K | 0.9% |
| Karyopharm Therapeutics Inc | Exited | −50,000 | −$671K | — |
| Acadia Pharmaceuticals Inc | Trimmed | −21,405 | −$327K | 0.5% |
| Exelixis Inc | New | +13,555 | +$292K | 0.6% |
| A Avexis Inc | Exited | −2,275 | −$281K | — |
| UP Ultragenyx Pharmaceutical In | Trimmed | −980 | −$75.3K | 1.1% |
Showing the 10 largest of 36 changes.
quarter ended March 31, 2018 · filed May 15, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sage Therapeutics Inc | Exited | −71,000 | −$11.7M | — |
| Nektar Therapeutics | Trimmed | −68,639 | −$7.29M | 4.9% |
| Bristol Myers Squibb Co | Exited | −90,000 | −$5.52M | — |
| Merck & Co Inc | Exited | −83,700 | −$4.71M | — |
| I Ignyta Inc | Exited | −170,500 | −$4.55M | — |
| AP Alexion Pharmaceuticals Inc | Exited | −35,000 | −$4.19M | — |
| Astrazeneca PLC | Exited | −120,000 | −$4.16M | — |
| Pfizer Inc | Exited | −112,300 | −$4.07M | — |
| SS SPDR Series Trust | Trimmed | −41,200 | −$3.61M | 4.1% |
| Alnylam Pharmaceuticals Inc | Trimmed | −29,384 | −$3.5M | 3.2% |
Showing the 10 largest of 63 changes.
quarter ended December 31, 2017 · filed February 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sage Therapeutics Inc | New | +71,000 | +$11.7M | 10.1% |
| IT Ishares Tr | Added | +25,000 | +$2.67M | 3.5% |
| DS Direxion Shs ETF Tr | Exited | −16,002 | −$1.37M | — |
| PT Proqr Thrapeutics N V | New | +307,692 | +$992K | 0.9% |
| Nektar Therapeutics | Trimmed | −12,258 | −$732K | 4.8% |
| Alnylam Pharmaceuticals Inc | Trimmed | −4,395 | −$558K | 4.7% |
| QI Quintiles Ims Holdings Inc | Exited | −5,413 | −$515K | — |
| Neurocrine Biosciences Inc | Trimmed | −5,440 | −$422K | 0.3% |
| JT Juno Therapeutics Inc | Trimmed | −9,132 | −$417K | 0.2% |
| Illumina Inc | Trimmed | −1,518 | −$332K | 1.8% |
Showing the 10 largest of 36 changes.
Loading...
